Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

被引：0
|
作者：
Berenson, James R.
Cohen, Alexa
Spektor, Tanya M.
Lashkari, Ashkan
Mackintosh, Roy
Bessudo, Alberto
Jhangiani, Haresh
Gabrail, Nashat
Nakhoul, Ibrahim
Kubba, Samir
Neidhart, Jeffrey D.
Tina, Maluso
Swift, Regina
Vescio, Robert
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3106
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma
    Scott, Lesley J.
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2011, 25 (05) : 333 - 337
  • [32] Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial
    Sanchez, Larysa
    Wang, Yucai
    McBride, Laura
    Bilotti, Elizabeth
    Vesole, David H.
    Richter, Joshua
    Biran, Noa
    Anand, Palka
    Ivanovski, Kristin
    McNeill, Ann
    Siegel, David
    BLOOD, 2015, 126 (23)
  • [33] Combination of ixazomib, pomalidomide and dexamethasone in the treatment of multiple myeloma in relapse and refractory to lenalidomide
    Stocker, Nicolas
    HEMATOLOGIE, 2018, 24 (04): : 261 - 262
  • [34] Pomalidomide-dexamethasone combination is efficient in lenalidomide-refractory multiple myeloma
    Coman, Tereza
    HEMATOLOGIE, 2010, 16 (06): : 410 - 411
  • [35] NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
    Burke, Martyn J.
    George, Elisabeth
    Adler, Amanda I.
    LANCET ONCOLOGY, 2015, 16 (05): : 492 - 493
  • [36] Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
    Mark, Tomer
    Falkenstein, Angelica
    Kish, Jonathan
    FUTURE ONCOLOGY, 2022, 18 (05) : 553 - 564
  • [37] Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
    Gueneau, Pauline
    Chretien, Marie-Lorraine
    Cransac-Miet, Amelie
    Aho, Ludwig Serge
    Lafon, Ingrid
    Favennec, Camille
    Guy, Julien
    Caillot, Denis
    Boulin, Mathieu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 518 - 525
  • [38] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M. A.
    Swern, A. S.
    Li, J. S.
    Hussein, M.
    Weiss, L.
    Nagarwala, Y.
    Baz, R.
    BLOOD CANCER JOURNAL, 2014, 4 : e257 - e257
  • [39] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    M A Dimopoulos
    A S Swern
    J S Li
    M Hussein
    L Weiss
    Y Nagarwala
    R Baz
    Blood Cancer Journal, 2014, 4 : e257 - e257
  • [40] The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function
    Weber, D. M.
    Spencer, A.
    Wang, M.
    Chen, C.
    Attal, M.
    Niesvizky, R.
    Prince, M.
    Yu, Z.
    Knight, R.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345